Presentation is loading. Please wait.

Presentation is loading. Please wait.

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC  Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,

Published byBrenda Manning Modified over 5 years ago

Similar presentations

Presentation on theme: "Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC  Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,"— Presentation transcript:

1 Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC  Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen, MD, Tao Jiang, MD, Xue Wu, PhD, Xiaoling Tong, MSc, Yang W. Shao, PhD, Songbing Qin, MD, Caicun Zhou, MD  Journal of Thoracic Oncology  Volume 12, Issue 6, Pages e65-e68 (June 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Multiple mutations on EGFR Leu792 were identified in three subjects with acquired resistance to osimertinib. For each subject, the top panel shows the treatment time line. Orange triangles indicate the time points at which clinical samples were collected. Sample types are marked below. The middle panel for each subject is the integrative genomics viewer viewing of next-generation sequencing reads aligned to human hg19 reference genome. C→T, T→A, and G→C substitutions are colored red, green, and blue, respectively. Schematic diagram in the bottom panel for each subject summarizes the allelic correlation of L792F/Y/H mutations to T790M and C797S. FFPE, formalin-fixed paraffin embedded; PR, partial response; PD, progressive disease; SD, stable disease. Journal of Thoracic Oncology  , e65-e68DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Structural prediction of EGFR L792F/Y/H mutants in complex with osimertinib. (A) Coordinates of wild-type EGFR and osimertinib complex (identifier 4ZAU) was downloaded from the Protein Data Bank and remodeled in PyMOL software. Yellow dotted lines indicate the bonds between osimertinib and the tyrosine kinase domain of EGFR, and the amino acids that were involved in forming hydrogen bonds or covalent bonds are indicated by orange arrows. (B–D) Mutating Leu792 to Tyr (Y), Phe (F), or His (H) results in a structural collision between mutated residue and osimertinib (red disks indicated by black arrows). Journal of Thoracic Oncology  , e65-e68DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC  Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,"

Similar presentations

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma  Karen L. Reckamp, MD, Vladislava O. Melnikova,

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma  Karen L. Reckamp, MD, Vladislava O. Melnikova,
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,
EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma  Maria I. Toki, MD,

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma  Maria I. Toki, MD,
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
The Genetic Basis of White Tigers

The Genetic Basis of White Tigers
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance.

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance.
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,
Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer  Inbar Nardi-Agmon, MD, Manal Abud-Hawa, MSc, Ori Liran, MSc, Naomi.

Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer  Inbar Nardi-Agmon, MD, Manal Abud-Hawa, MSc, Ori Liran, MSc, Naomi.
Novel mutations and polymorphisms in the CFTR gene associated with three subtypes of congenital absence of vas deferens  Xiaojian Yang, M.D., Qipeng Sun,

Novel mutations and polymorphisms in the CFTR gene associated with three subtypes of congenital absence of vas deferens  Xiaojian Yang, M.D., Qipeng Sun,
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Similar presentations

Ads by Google